SCHEMBL7679208

SCHEMBL7679208

CC(C)(C)OC(=O)NC(N)(CC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.47
PPARA Q07869 1/20 0.45
KLK7 P49862 1/20 0.44
KLK5 Q9Y337 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CTSS P25774 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CTSL P07711 1/20 0.42
AKT1 P31749 3/20 0.41
IDO1 P14902 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18154447 0.82 SYK (0.47) SYKPPARAKLK7KLK5ALDH1A1
SCHEMBL560683 0.80 ALDH1A1 (0.49) SYKPPARAKLK7KLK5ALDH1A1
SCHEMBL560684 0.80 ALDH1A1 (0.49) SYKPPARAKLK7KLK5ALDH1A1
SCHEMBL5318899 0.79 CYP2D6 (0.36) MEN1KMT2ACTSSCA12CA1
SCHEMBL999885 0.79 KMT2A (0.45) KMT2A
SCHEMBL999886 0.79 KMT2A (0.45) KMT2A
SCHEMBL560838 0.79 ALDH1A1 (0.51) SYKPPARAKLK7KLK5ALDH1A1
SCHEMBL643209 0.78 SYK (0.46) SYKPPARAALDH1A1MEN1KMT2A
SCHEMBL27341323 0.78 ALDH1A1 (0.46) SYKPPARAKLK7KLK5ALDH1A1
SCHEMBL27847368 0.78 ALDH1A1 (0.46) SYKPPARAKLK7KLK5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479579-B2 Therapeutic compounds and methods REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2022-10-25 US disclosed
US-20210277055-A1 THERAPEUTIC COMPOUNDS AND METHODS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-09-09 US disclosed
US-6344452-B1 GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC ZERIA PHARMACEUTICALS CO., LTD. (JP) 2002-02-05 US disclosed
EP-1085014-A1 1,5-BENZODIAZEPINE DERIVATIVES Zeria Pharmaceutical Co., Ltd. (JP) 2001-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479579-B2 Therapeutic compounds and methods SNCA, PARK7, PSEN2 SYK 3900/4885PPARA 2032/4885KLK7 4287/4885
US-20210277055-A1 THERAPEUTIC COMPOUNDS AND METHODS SNCA, PARK7, PSEN2 SYK 3900/4885PPARA 2032/4885KLK7 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.